SAN DIEGO, Sept. 15, 2021 /PRNewswire/ -- Halozyme
Therapeutics, Inc. (NASDAQ: HALO) today announced that Elaine Sun, senior vice president and chief
financial officer, will present at the 2021 Cantor Virtual Global
Healthcare Conference on Tuesday, September 28,
2021 at 1:20 p.m. Eastern Time / 10:20 a.m.
Pacific Time.
An audio-only direct link of the presentation can be accessed
through the "Investors" section of www.halozyme.com, and a
recording will be made available for 6 months following the event.
To access the link, please visit Halozyme's website approximately
10 minutes prior to the presentation to register and download any
necessary audio software.
About Halozyme
Halozyme is a biopharmaceutical company
bringing disruptive solutions to significantly improve patient
experiences and outcomes for emerging and established therapies.
Halozyme advises and supports its biopharmaceutical partners in key
aspects of new drug development with the goal of improving
patients' lives while helping its partners achieve global
commercial success. As the innovators of the ENHANZE®
technology, which can reduce hours-long treatments to a matter of
minutes, Halozyme's commercially-validated solution has touched
more than 500,000 patient lives via five commercialized products
across more than 100 global markets. Halozyme and its world-class
partners are currently advancing multiple therapeutic programs
intended to deliver innovative therapies, with the potential to
improve the lives of patients around the globe. Halozyme's
proprietary enzyme rHuPH20 forms the basis of the
ENHANZE® technology and is used to facilitate the
delivery of injected drugs and fluids, potentially reducing the
treatment burden of other drugs to patients. Halozyme has licensed
its ENHANZE® technology to leading pharmaceutical and
biotechnology companies including AbbVie, Alexion, argenx, Baxalta,
Bristol-Myers Squibb, Horizon, Janssen, Lilly, Pfizer, Roche and
ViiV Healthcare. Halozyme derives revenues from these
collaborations in the form of milestones and royalties as the
Company's partners make progress developing and commercializing
their products being developed with ENHANZE®. Halozyme
is headquartered in San Diego. For
more information visit Halozyme.com and connect with us on LinkedIn
and Twitter.
Contact:
Al
Kildani
Vice President, Investor Relations and Corporate Communications
858-704-8122
ir@halozyme.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/halozyme-to-participate-in-the-2021-cantor-virtual-global-healthcare-conference-301378066.html
SOURCE Halozyme Therapeutics, Inc.